ArticleCancer science2021

Novel RAF/MEK inhibitor CH5126766/VS-6766 has efficacy in combination with eribulin for the treatment of triple-negative breast cancer.

Hisako Ono et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.